Pablo Scodeller
Principal Investigator
Consejo Superior de Investigaciones Científicas
I'm working on
4 months ago
Drug Delivery, Oncology, Neurodegeneration, Translational R&D
About
Pablo Scodeller advances peptide-enabled delivery for cancer and neurodegenerative disease. He holds 3 issued patents spanning targeted delivery to tumor-associated macrophages and injured brain tissue. Work bridges nanoparticles, peptide-drug conjugates, and translational immuno-oncology.
Partnering listings
Learn more
Consejo Superior de Investigaciones Científicas
Orally active peptide-drug conjugate targeting CD206+ macrophages for crohn's disease treatment
Dextrimu is an oral peptide-drug conjugate that selectively targets CD206+ macrophages in Crohn's disease. It combines a CD206-targeting peptide (TrimUNO) with dexamethasone to modulate inflammatory macrophages with deep...
TechnologyConceptualUniversity
Consejo Superior de Investigaciones Científicas
Immunotherapy enhancement with MACTIDE-V peptide-drug conjugate for cancer treatment
MACTIDE-V is an innovative peptide-drug conjugate targeting tumor-associated macrophages to reprogram them for enhanced antitumoral activity, particularly in metastatic triple negative breast cancer. It aims to synergize...
TechnologyIn developmentUniversity
Pablo Scodeller
Principal Investigator
Consejo Superior de Investigaciones CientíficasWork experience
Top industry applications
Oncology & cancer therapeuticsPharmaceuticals and drug delivery
Expertise
Cell BiologyDrug DeliveryNeurodegenerationOncologyTranslational Science
Last updated May 2026
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.